Published in Cancer Weekly, July 18th, 2006
According to a study from the United States, "The purpose of the current study was to determine the toxicity and response of a fixed dose CSF etoposide in the treatment of patients with newly diagnosed NM. NM reportedly occurs in 1% to 5% of patients with known cancer."
"Currently available treatment options are limited and provide only modest benefit. Twenty-seven patients (median age, 55 yrs) with clinically and cytologically documented NM received intra-CSF etoposide. Tumor histologies included lung (8 patients), breast (5 patients), primary brain tumor (4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly